Arsenic-induced dysfunction in relaxation of blood vessels. by Lee, Moo-Yeol et al.
Arsenic is a ubiquitous element found in sev-
eral forms in foods and environmental media,
such as soil, air, and water. The primary route
of human exposure is through ingestion of
arsenic-contaminated foods and drinking
water. Although foods contain substantial lev-
els of arsenic, it is primarily in organic form
and of relatively low toxicity compared to the
inorganic forms (NRC 1999). In contrast, the
predominant form in drinking water is inor-
ganic arsenic, which is both highly toxic and
readily bioavailable. Chronic ingestion of
arsenic-contaminated drinking water is there-
fore considered the major pathway behind the
risk to human health (Bagla and Kaiser 1996).
In humans, chronic arsenic exposure has
been associated with diverse health effects
including cancer, hyperkeratosis, diabetes,
and cardiovascular disease (Bates et al. 1992;
Col et al. 1999; Engel et al. 1994; Tseng
et al. 2000). Cardiovascular effects associated
with high levels of arsenic in drinking water
include atherosclerosis, hypertension, cere-
brovascular diseases, ischemic heart disease,
and peripheral vascular disorders such as
blackfoot disease (resulting from gangrene
caused by obstruction of peripheral blood
vessels) (Chen et al. 1988; Chiou et al. 1997;
Rahman et al. 1999; Tseng 1977; Wang et al.
2002). In a previous study we demonstrated
that arsenic increased the susceptibility of
platelets to aggregate, resulting in enhanced
risk of arterial thrombosis, which could be a
causal factor in the development of cardiovas-
cular disease (Lee et al. 2002). However, the
diversity of cardiovascular diseases arising
from chronic arsenic exposure also raises the
possibility that arsenic may alter the normal
functioning of blood vessels, which are
involved in various cardiovascular disorders.
Blood vessels maintain a balanced vaso-
motor tone mediated through biochemical
signaling between endothelial cells and
smooth muscle cells (Moncada et al. 1991).
Endothelial cells can produce nitric oxide
(NO) by endothelial nitric oxide synthase
(eNOS), which causes vascular relaxation
through guanosine 3´,5´-cyclic monophos-
phate (cGMP) synthesis by the activation of
guanylate cyclase within the smooth muscle
cells (Ignarro 1989). Impairment of these cel-
lular functions disrupts vascular homeostasis,
leading to excessive vasoconstriction, which
could ultimately contribute to various vascu-
lar diseases (Bell et al. 1998). In fact, altered
vasomotor tone can lead to acute vasospasm,
microcirculatory ischemia, and increased sys-
temic blood pressure (Alexander 1995;
Luscher et al. 1993; Sellke et al. 1997).
Previous studies have implied that arsenic
can alter normal vasomotor function.
Carmignani et al. (1985) reported that chronic
administration of arsenite to rats and rabbits
caused signiﬁcant increase in peripheral vascu-
lar resistance, which suggests that arsenite may
induce impaired vascular function. Pi et al.
(2000) showed that the concentration of
nitrite/nitrate in the blood, which is indicative
of endogenous NO levels, was significantly
lower in an arsenic-exposed population than in
the normal population. These studies imply
that arsenic might disrupt normal vascular
function. Therefore, in the present study we
investigated the effects of arsenite on relax-
ation of blood vessels by using isolated aortic
rings in an organ-bath system in an effort to
provide new insight into arsenic-induced vas-
cular dysfunction.
Materials and Methods
Materials. The following chemicals were pur-
chased from Sigma Chemical Co. (St. Louis,
MO, USA): sodium arsenite (As3+), sodium
arsenate (As5+), dimethylarsinic acid (DMA),
acetylcholine, phenylephrine, sodium nitro-
prusside (SNP), 8-Br-cGMP, and Dowex
AG50W-X8 (100–200 mesh). Monomethyl-
arsonic acid (MMA) was obtained from
Chem Service (West Chester, PA, USA), and
a cGMP radioimmunoassay kit was obtained
from Amersham (Buckinghamshire, UK).
Human aortic endothelial cells (HAEC) and
the endothelial cell growth media (EGM) kit
were purchased from Clonetics Corporation
(Walkersville, MD, USA). Minimum essen-
tial media (MEM) was supplied by Life
Technologies (Rockville, MD, USA), and all
other reagents used were of the highest purity
available.
Animals. We used male Sprague-Dawley
rats (Dae Han BioLink, Chungbuk, Korea)
weighing 300–400 g in all experiments.
Before the experiments, the animals were
acclimated for 1 week in a laboratory animal
facility maintained at constant temperature
and humidity with a 12-hr light/dark cycle.
Food and water were provided ad libitum.
Preparation of blood vessels in organ bath.
Rats were killed by decapitation and then
exsanguinated. We carefully isolated the tho-
racic aorta and cut it into ring segments. Aortic
rings without endothelium were prepared by
gently rubbing the intimal surface of the aortic
rings with a wooden stick. The aortic rings
were treated with As3+ or the vehicle (saline) in
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Several epidemiological studies have suggested that exposure to arsenic is strongly correlated with
the development of cardiovascular diseases such as hypertension. To determine whether arsenic
affects vasomotor tone in blood vessels, we investigated the effect of arsenic on vasorelaxation using
isolated rat aortic rings in an organ-bath system. Treatment with arsenite inhibited acetylcholine-
induced relaxation of the aortic rings in a concentration-dependent manner, whereas several other
arsenic species did not have any effect. Consistent with these ﬁndings, the levels of guanosine 3´,5´-
cyclic monophosphate (cGMP) in the aortic rings were signiﬁcantly reduced by arsenite treatment.
In cultured human aortic endothelial cells, treatment with arsenite resulted in a concentration-
dependent inhibition of endothelial nitric oxide synthase (eNOS). In addition, higher concentra-
tions of arsenite decreased the relaxation induced by sodium nitroprusside (an NO donor) and
8-Br-cGMP (a cGMP analog) in aortic rings without endothelium. These in vitro results indicate
that arsenite is capable of suppressing relaxation in blood vessels by inhibiting eNOS activity in
endothelial cells and by impairing the relaxation machinery in smooth muscle cells. In vivo studies
revealed that the reduction of blood pressure by acetylcholine infusion was signiﬁcantly suppressed
after arsenite was administered intravenously to rats. These data suggest that an impairment of
vasomotor tone due to arsenite exposure may be a contributing factor in the development of cardio-
vascular disease. Key words: arsenic, arsenite, blood vessels, cardiovascular disease, endothelial nitric
oxide synthase, nitric oxide, vasorelaxation. Environ Health Perspect 111:513–517 (2003).
doi:10.1289/ehp.5916 available via http://dx.doi.org/ [Online 16 December 2002]
Research | ArticlesMEM with 100 U/mL penicillin and 100
µg/mL streptomycin at 37°C in a 95%
air/5% CO2 incubator for 14 hr. The rings
were then mounted in four-channel organ
baths filled with Krebs-Ringer solution (pH
7.4): 115.5 mM NaCl, 4.6 mM KCl, 1.2
mM KH2PO4, 1.2 mM MgSO4, 2.5 mM
CaCl2, 25.0 mM NaHCO3, and 11.1 mM
glucose. The organ baths were continuously
gassed with 95% O2/5% CO2 and maintained
at 37°C. The rings were stretched gradually to
an optimal resting tension of 2 g and equili-
brated for 30 min. We measured the change in
tension isometrically with Grass FT03 force
transducers (Grass Instrument Co., Quincy,
MA, USA) and recorded the change using
the AcqKnowledge III computer program
(BIOPAC Systems Inc., Goleta, CA, USA).
To investigate the effect of As3+ on
endothelium-dependent relaxation, acetyl-
choline was used as an agonist. The aortic rings
were precontracted submaximally by adding
phenylephrine, and acetylcholine was then
cumulatively added to the organ bath to obtain
concentration-relaxation curves. To examine
the effects of As3+ on the NO donor-induced
relaxation and on direct cGMP-dependent
relaxation, sodium nitroprusside was used as
the NO donor and 8-bromoguanosine 3´,5´-
cyclic monophosphate (8-Br-cGMP) was used
as the cGMP analog. Relaxation was expressed
as the percent decrease in contractile tone
elicited by phenylephrine.
Determination of eNOS activity. We deter-
mined eNOS activity by measuring the conver-
sion of [3H]-L-arginine to [3H]-L-citrulline.
These amino acids were separated by anion
exchange chromatography using a modiﬁcation
of the method of Bredt and Snyder (1990). We
maintained HAEC (six to eight passages) in the
EGM kit at 37°C in a 95% air/5% CO2
incubator. Before the experiments, 4 × 104 cells
were seeded into 12-well plates and grown for
48 hr. After the HAEC were treated with vari-
ous concentrations of As3+ for 14 hr, they were
incubated for 20 min in HEPES buffer (pH
7.4): 140 mM NaCl, 2.7 mM KCl, 1.0 mM
MgCl2, 5.0 mM glucose, 25 mM HEPES, and
3 µCi/mL [3H]-L-arginine. The cells were
washed twice with ice-cold Ca2+-free buffer
containing 5 mM EDTA, and then 0.3 M
HClO4 was added. The tissue extract was then
neutralized with 3 M K2CO3 and centrifuged
at 12,000 × g for 2 min; the supernatants were
applied to columns containing Dowex
AG50W-X8 (Na+ form), and the eluted [3H]-
L-citrulline was measured by scintillation count-
ing. We determined protein content by the
method of Lowry et al. (1951).
Measurement of superoxide anion genera-
tion. We determined generation of superoxide
anions by lucigenin-induced chemilumines-
cence. Aortic rings were placed in a Krebs-
Ringer solution continuously gassed with 95%
O2/5% CO2 and allowed to equilibrate for
30 min at 37°C. A mixture of 2 mL Krebs-
Ringer solution with 0.25 mM lucigenin was
prepared in a scintillation tube and mixed
with various concentrations of As3+. Aortic
rings were then added to each tube, and
chemiluminescence was measured for 60 min
using a luminometer (Berthold, Germany).
Measurement of cGMP levels. We treated
rat aortic rings with As3+ or saline for 14 hr as
described previously (Lee et al. 2001). For the
experiments in which we examined cGMP lev-
els stimulated by an agonist, 10–7 M acetyl-
choline was added to the organ bath for 1 min.
The reactions were immediately stopped with
liquid nitrogen, and the tissue was homoge-
nized in 1 mL ice-cold 6% trichloroacetic acid.
The homogenate was centrifuged at 13,600 ×
g for 15 min at 4°C. The supernatant was
extracted with water-saturated ether. We
assayed extracts for cGMP levels by radioim-
munoassay (RIA) using a [125I]-cGMP RIA kit
(Amersham) according to the procedure
described by the manufacturer. We determined
protein content from the pellet according to
the method of Lowry et al. (1951).
Measurement of blood pressure change
induced by acetylcholine. Rats were anes-
thetized with phenobarbital (50 mg/kg,
intraperitoneal). A catheter of polyethylene
PE-50 tubing (Clay Adams, Sparks, MD,
USA) filled with heparinized saline (100
U/mL) was placed in the carotid artery for the
measurement of blood pressure, and a catheter
of polyethylene PE-10 fused to PE-50 tubing
was placed in the jugular vein for the adminis-
tration of drugs. Catheters were tunneled sub-
cutaneously and exteriorized at the back of the
neck. Wounds were sutured and cleaned with
alcohol. We began experiments after a 1-day
recovery period. On the day of the experi-
ment, the arterial catheter was connected to a
pressure transducer (BIOPAC Systems Inc.),
and blood pressure was measured using the
AcqKnowledge III computer program. Blood
pressure was allowed to stabilize for a mini-
mum of 30 min before treatment began. To
determine the effects of As3+ on blood pres-
sure reduction induced by acetylcholine, we
administered As3+ solution (1 mg/kg) by an
intravenous bolus injection into the jugular
vein. In the controls, equivalent amounts of
saline were injected. After 2 hr, the rats were
infused with 10 µg/kg/min acetylcholine for 2
min via the jugular vein, and the change in
blood pressure in response to acetylcholine
was monitored simultaneously. Infusions
were performed with a Harvard syringe pump
(Southnatick, MA, USA) at a rate of 0.1
mL/min.
Statistical analysis. We calculated the
means and standard errors of means for all
treatment groups. The data were subjected to
one-way analysis of variance followed by
Duncan’s multiple range test to determine
which means were signiﬁcantly different from
the control. In all cases, a p value of < 0.05
was used to determine signiﬁcance.
Results
To determine whether arsenic affects relax-
ation of blood vessels, we treated intact aor-
tic rings with various concentrations of As3+
for 14 hr. Phenylephrine was applied to pre-
contract the rings, followed by cumulative
addition of acetylcholine to obtain concen-
tration–relaxation curves (Figure 1A). As3+
suppressed the relaxation induced by acetyl-
choline in a concentration-dependent man-
ner. We also investigated the effects of the
pentavalent inorganic species (As5+) and two
major metabolites, MMA and DMA, on the
inhibition of acetylcholine-induced vasorelax-
ation (Figure 1B). However, As3+, MMA, and
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Figure 1. Inhibitory effect of As3+ on relaxation of aortic rings induced by acetylcholine. After intact aortic
rings were treated with (A) various concentrations of As3+ and (B) other species of arsenic (100 µM each)
for 14 hr, 1 µM phenylephrine was added to precontract the aortic rings and then increasing concentra-
tions of acetylcholine were added in a cumulative manner. Concentration–response curves to acetyl-
choline were determined with relaxation expressed as the percent decrease in contractile tone elicited by
phenylephrine. The values of curves are means ± SEM of four to ﬁve independent experiments.
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▲DMA failed to inhibit the acetylcholine-
induced relaxation.
Acetylcholine stimulates eNOS to produce
NO in endothelium, which results in the
relaxation of smooth muscle (Wanstall et al.
2001). To examine whether As3+ inhibits NO
synthesis by endothelial cells, we investigated
the effect of As3+ on eNOS activity in cultured
HAEC. As3+ reduced eNOS activity in a con-
centration-dependent manner (Figure 2A),
suggesting that As3+ can suppress vascular NO
production in endothelial cells. Others have
reported that As3+ can generate superoxide
anions in cultured endothelial cells and
smooth muscle cells (Lynn et al. 2000; Smith
et al. 2001). Superoxide anions interact with
NO to form peroxynitrite, resulting in sup-
pression of vascular relaxation by blocking the
NO pathway (Pryor and Squadrito 1995). To
determine if superoxide anions generated by
As3+ may play a role in the suppression of vas-
cular relaxation, we treated aortic rings with
intact endothelium with As3+, and superoxide
production was evaluated by measuring luci-
genin-induced chemiluminescence. Increased
chemiluminescence was not observed at any
concentration of As3+ tested (Figure 2B).
NO released from endothelium elicits vas-
cular relaxation by increasing the levels of
cGMP in smooth muscle (Robertson et al.
1993). To determine the effects of As3+ on
the NO-dependent pathway, we measured
the accumulation of cGMP in aortic rings.
The basal cGMP levels in the aortic rings
were signiﬁcantly decreased by As3+ treatment
in a concentration-dependent manner (Figure
3A). After stimulation with 10–7 M acetyl-
choline, As3+ again significantly reduced
cGMP levels, even though the cGMP levels
were 30 times greater due to the acetylcholine
stimulation (Figure 3B). However, unlike the
results for acetylcholine-induced relaxation
(Figure 1A), no difference in cGMP level was
found between the 25- and 50-µM As3+
treatments, suggesting that arsenic may inter-
fere with some relaxation mechanism in addi-
tion to inhibiting endothelium-dependent
NO production.
Therefore, using aortic rings without
endothelium, we examined the effect of As3+
on relaxation induced by SNP, a direct NO-
releasing agent. Treatment with As3+ inhibited
vasorelaxation induced by SNP to a lesser
extent (Figure 4A) than the vasorelaxation
induced by acetylcholine. As3+ at a concentra-
tion of 25 µM did not suppress SNP-induced
relaxation, but 50 µM As3+ showed signiﬁcant
inhibition. Consistent with this ﬁnding, when
we investigated the effect of As3+ on relaxation
induced by the cGMP analog, 8-Br-cGMP in
aortic rings without endothelium, only 50 µM
As3+ resulted in signiﬁcant reduction of cGMP
analog-induced relaxation (Figure 4B). These
results suggested that 50 µM As3+ could inter-
fere with the cGMP-dependent relaxation
machinery of smooth muscle in blood vessels.
To verify the effects of As3+ on blood ves-
sels in vivo, we monitored the change in
blood pressure after intravenous infusion of
acetylcholine into conscious rats (Figure 5).
An intravenous bolus of As3+ had no effect on
basal blood pressure (Figure 5A). When rats
were infused with 10 µg/kg/min acetylcholine
2 hr after As3+ treatment (Figure 5C), the
reduction of blood pressure induced by
acetylcholine was significantly suppressed
compared to the control group (10.8 ± 3.5 vs.
31.3 ± 4.7 mmHg) (Figure 5B). These results
suggest that As3+ caused suppression of
vasorelaxation induced by acetylcholine in
vivo. This confirms the previous in vitro
results shown in Figure 1A.
Discussion
This is the ﬁrst study to evaluate the effects of
As3+ on vasomotor function in vitro and in
vivo. We have shown that As3+ inhibits the
vascular relaxation induced by acetylcholine
in a concentration-dependent manner and
that possible mechanisms are the inhibition of
NO production in endothelial cells and the
suppression of cGMP-dependent relaxation
mechanisms in smooth muscles. These in
vitro results were consistent with in vivo
results (Figure 5) in which As3+ suppressed
the reduction of blood pressure by acetyl-
choline in conscious rats. Our ﬁndings corre-
late well with a previous study reporting that
serum concentrations of NO metabolites were
decreased in a population exposed to arsenic
in drinking water (Pi et al. 2000). In addi-
tion, this As3+-induced suppression in vitro
was still observed after the removal of residual
As3+ by changing the incubation medium,
suggesting that the As3+-induced effect was
irreversible and that damaged blood vessels
might not recover even after As3+ has dis-
appeared from the bloodstream.
Articles | Arsenic-induced dysfunction in blood vessels
Environmental Health Perspectives • VOLUME 111 | NUMBER 4 | April 2003 515
0.4
0.3
0.2
0.1
0.0
15
10
5
0
c
G
M
P
 
(
p
m
o
l
/
m
g
 
p
r
o
t
e
i
n
)
0
A B
As3+ (µM)
10 25
*
25 05 0
As3+ (µM)
50 10
* *
c
G
M
P
 
(
p
m
o
l
/
m
g
 
p
r
o
t
e
i
n
)
Figure 2. Effects of As3+ on eNOS activity in human aortic endothelial cells and superoxide production in
aortic rings. (A) After As3+ was added to HAEC for 14 hr, the activity of eNOS was determined by the for-
mation of L-citrulline from L-arginine, as described in “Materials and Methods.” (B) Several concentrations
of As3+ were added to aortic rings and superoxide anions was measured by lucigenin-induced chemilumi-
nescence. Menadione (MEN; 10 µM) was used as positive control. Values are means ± SEM of (A) ﬁve to
six and (B) three independent experiments. 
*Signiﬁcant difference from control (p < 0.05).
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Figure 3. Effects of As3+ on cGMP levels of aortic rings. After aortic rings were treated with As3+ for 14 hr,
(A) cGMP levels in basal state and (B) cGMP levels accumulated by 10–7 M acetylcholine were deter-
mined by RIA method as described in “Materials and Methods.” Values are means ± SEM of ﬁve to seven
independent experiments. 
*Signiﬁcant differences from corresponding control (p < 0.05).Several epidemiologic studies have
reported that arsenic-contaminated drinking
water causes various types of cardiovascular
disease such as blackfoot disease, atherosclero-
sis, cerebrovascular disorders, and hyperten-
sion (Chen et al. 1988; Chiou et al. 1997;
Rahman et al. 1999; Tseng 1977; Wang et al.
2002). Recently, the effect of arsenic on
platelets has been suggested as a key mecha-
nism in the development of these cardiovas-
cular diseases (Lee et al. 2002). Blood vessels,
however, are another tissue important in the
development of cardiovascular diseases.
Dysfunction in blood vessels disrupts the bal-
ance in vasomotor tone between relaxation
and contraction, with vasoconstriction pre-
dominating and ultimately leading to possible
increased risk for development of vascular dis-
eases such as hypertension and atherosclerosis
(Lefer et al. 1991; Luscher et al. 1993;
Rubanyi 1993; Vanhoutte 1997). Because
our data showed that As3+ could suppress
endothelium-dependent vasorelaxation with
subsequent changes in vasomotor tone in
blood vessels, we propose arsenic-induced
dysfunction in blood vessels as an alternative
mechanism for arsenic-associated cardiovascu-
lar disease observed in human populations.
Treatment with As3+ did not result in con-
centration-dependent inhibition of vasorelax-
ation induced by SNP (Figure 4A) compared
to the results obtained by acetylcholine (Figure
1A). As3+ at a concentration of 25 µM did not
inhibit SNP-induced relaxation but did
inhibit acetylcholine-induced relaxation, sug-
gesting that 25 µM As3+ may interfere with
NO production in endothelial tissue. This
conclusion is supported by our finding that
As3+ can signiﬁcantly inhibit eNOS activity in
cultured human aortic endothelial cells
(Figure 2A). In addition to interfering with
NO generation in aortic endothelium, higher
concentrations of As3+ may also disrupt the
relaxation mechanisms in smooth muscles.
Several lines of evidence support this view.
First, only 50 µM concentrations of As3+
showed an inhibitory effect on SNP-induced
relaxation in aortic rings without endothelium
(Figure 4A). Second, unlike acetylcholine-
induced vasorelaxation (Figure 1A), levels of
acetylcholine-stimulated cGMP in aortic rings
showed no difference between treatments with
25 or 50 µM As3+ (Figure 3B). Third, treat-
ment with 50 µM As3+ resulted in signiﬁcant
reduction of cGMP analog-induced vasorelax-
ation in aortic rings without endothelium
(Figure 4B). These results suggest that impair-
ment of NO generation in endothelium and
impairment of cGMP-dependent relaxation
mechanisms in smooth muscles depended on
the concentrations of As3+ that blood vessels
were exposed to.
As3+ is reported to stimulate the formation
of reactive oxygen species (ROS) in vascular
endothelial and smooth muscle cells, mainly
via NADH/NADPH oxidase (Lynn et al.
2000; Smith et al. 2001); thus, the generation
of superoxide could elicit the reduced relax-
ation due to elimination of NO. Therefore,
we considered the possibility that superoxide
production is involved in suppression of
vasorelaxation by As3+. However, we detected
no signiﬁcant increase in ROS generation in
intact aortic rings when measuring superoxide
anions with the chemiluminescent probe luci-
genin (Figure 2B). These contradictory results
might be explained by the differences in exper-
imental systems (we used aortic rings in an
organ-bath system and the previous studies
used a cell culture system), but the exact rea-
son for this discrepancy is currently unknown.
In any case, our results suggest that superoxide
generation does not play an important role in
the suppression of vasorelaxation by As3+.
Our study revealed that higher concentra-
tions of As3+ inhibited cGMP-dependent
relaxation of smooth muscle in aortic rings
isolated from rats. Arsenic is well known to
induce heat-shock proteins (Del Razo et al.
2001), a large family of proteins whose
expression is usually induced by cellular stress.
Knoepp et al. (2000) reported that smooth
muscle relaxation induced by SNP and
forskolin, a adenylate cyclase activator, was
inhibited by cellular stresses such as heat
shock and As3+ via inhibition of the phospho-
rylation of heat shock protein 20, which is a
regulatory component of the actin-associated
cytoskeleton. However, those effects were
observed in bovine carotid artery, whereas our
aortic rings were isolated from rats.
Furthermore, 0.5 mM As3+ was used in those
experiments, which was 10 times higher than
the concentrations used in our experiment. In
fact, treatment with 0.5 mM As3+ resulted in
complete impairment of phenylephrine-
induced precontraction in rat artery (data not
shown), and thus the relaxation experiment
by acetylcholine was not feasible. Therefore, it
appears inappropriate to apply the explana-
tion of Knoepp’s group to our observation
that 50 µM As3+ could suppress the relaxation
Figure 5. Effect of intravenously administered As3+
on decrease in blood pressure by acetylcholine
infusion in rats. (A) Blood pressure changes by
As3+ bolus and saline infusion were monitored.
Decrease in blood pressure by acetylcholine infu-
sion (10 µg/kg/min) was measured via carotid
artery 2 hr after an intravenous bolus of (B) saline
or (C) As3+ [1 mg/kg]. Infusions were performed by
Harvard syringe pump at a rate of 0.1 mL/min for 2
min (indicated by line). Data are representative
tracings of ﬁve independent experiments.
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Figure 4. Effects of As3+ on relaxation induced by sodium nitroprusside and 8-Br-GMP in aortic rings with-
out endothelium. After aortic rings without endothelium were treated with As3+ for 14 hr, 1 µM phenyl-
ephrine was added to precontract the aortic rings and then relaxation was elicited by (A) cumulative
addition of SNP, NO donor and (B) 30 µM 8-Br-cGMP, a cGMP analog. Relaxation is expressed as percent-
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*Signiﬁcant difference from control (p < 0.05).machinery in smooth muscles. The exact
mechanism remains to be identiﬁed.
Previous study reported that the normal
concentration of arsenic in human plasma is
2.4 ± 1.9 µg/L and that this level may be
increased up to 38 µg/L with chronic arsenic
exposure (Heydorn 1970). Our in vivo
arsenic experiment showed significant sup-
pression of acetylcholine-induced vasorelax-
ation after only a 2-hr exposure (Figure 5), at
which time arsenic reached its plasma level of
less than 100 µg/L (data not shown). This
experimental arsenic exposure was therefore
not more than a factor of 3 greater than
arsenic levels to which human blood vessels
are exposed after chronic intake of arsenic-
contaminated drinking water. Considering
the facts that humans are more sensitive to
arsenic toxicity than are several other species
(Chan and Huff 1997), the concentration of
arsenic used in the current investigation could
be well within the range to induce cardiovas-
cular disease when humans drink arsenic-con-
taminated water for weeks or even years.
From this study, we determined that As3+
caused altered vascular tone by decreasing
vasorelaxation. The inhibitory effects may be
due to suppression of NO production mediated
by eNOS inhibition in endothelial cells and
interference of cGMP-dependent relaxation
machinery in smooth muscles (Figure 6). In
our in vivo study, As3+ treatment of rats
blocked the acetylcholine-induced hypotensive
effect. These results conﬁrm our in vitro obser-
vations and suggest that reduced vasorelaxation
may be a contributing factor in development
of cardiovascular diseases in populations
exposed to arsenic.
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Figure 6. Proposed mechanism for inhibitory effect
of As3+ on vasorelaxation. Abbreviations: Ach,
acetylcholine; GC, guanylate cyclase; GTP, guano-
sine triphosphate. As3+ causes altered vasomotor
tone by decreasing vasorelaxation induced by Ach.
This could be due to suppression of NO production
mediated by eNOS inhibition in endothelial cells
and interference of cGMP-dependent relaxation
machinery in smooth muscles.